Zacks Research Issues Pessimistic Estimate for EHC Earnings

Encompass Health Co. (NYSE:EHC) – Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for shares of Encompass Health in a report issued on Thursday, February 20th. Zacks Research analyst Z. Masood now forecasts that the company will post earnings per share of $1.19 for the quarter, down from their prior forecast of $1.23. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health’s Q2 2025 earnings at $1.16 EPS, Q3 2025 earnings at $1.13 EPS, FY2025 earnings at $4.67 EPS, Q1 2026 earnings at $1.30 EPS, Q2 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.21 EPS, FY2026 earnings at $5.19 EPS and FY2027 earnings at $5.67 EPS.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%.

A number of other research analysts have also recently issued reports on EHC. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. KeyCorp lifted their price objective on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Barclays lifted their price objective on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Finally, William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.67.

Encompass Health Trading Up 1.8 %

EHC opened at $100.65 on Monday. The business has a 50 day moving average of $96.08 and a 200-day moving average of $96.15. The stock has a market cap of $10.14 billion, a PE ratio of 22.57, a PEG ratio of 2.31 and a beta of 0.90. Encompass Health has a 52 week low of $73.68 and a 52 week high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84.

Institutional Trading of Encompass Health

Several large investors have recently modified their holdings of the company. CIBC Asset Management Inc grew its holdings in shares of Encompass Health by 3.5% in the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock worth $286,000 after acquiring an additional 100 shares during the period. Miracle Mile Advisors LLC grew its holdings in Encompass Health by 3.0% during the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock valued at $354,000 after purchasing an additional 112 shares during the period. US Bancorp DE grew its holdings in Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company’s stock valued at $127,000 after purchasing an additional 121 shares during the period. Signaturefd LLC grew its holdings in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company’s stock valued at $65,000 after purchasing an additional 125 shares during the period. Finally, CBIZ Investment Advisory Services LLC grew its holdings in Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after purchasing an additional 127 shares during the period. Institutional investors own 97.25% of the company’s stock.

Insider Buying and Selling

In related news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by corporate insiders.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 17th. Stockholders of record on Tuesday, April 1st will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s dividend payout ratio is currently 15.25%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.